Skip to content

Multimodal image-guided fusion targeted biopsy of the prostate

Multimodal image-guided fusion targeted biopsy of the prostate

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000028899
Enrollment
Unknown
Registered
2020-01-06
Start date
2019-12-25
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Gold Standard:prostate targeted biopsy guided by TRUS
Index test:prostate&#32
by&#32
and&#32
TRUS

Sponsors

Tongji hospital,Tongji Medical college, HUST
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Male > 18 years old; 2. High risk patients (serum PSA > 10 ng / ml) in the first diagnosis of prostate cancer meet any of the following requirement: digital rectal examination, transrectal prostate us, bone scan, CT or Mr prompt suspicious malignant lesions, bone pain); 3. Patients with biochemical recurrence of prostate cancer (serum PSA > 0.2 ng / ml); 4. Sign informed conset.

Exclusion criteria

Exclusion criteria: 1. Patients with severe heart disease, respiratory distress or hypotension; 2. Those unable to cooperate with PET examination; 3. Prostate puncture within 1 month; 4. Cryosurgery / external irradiation / high-energy focused ultrasound knife within 1 year; 5. Brachytherapy within 2 years.

Design outcomes

Primary

MeasureTime frame
SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactZhu Xiaohua

Department of Nucelar Meddicine, Tongji Hospital, Tongji Medical College, HUST

evazhu@vip.sina.com+86 13971513770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026